You are invited to watch this series of six video chapters from a live medical expert broadcast that took place on 28 September 2018. Professor Richard Schlenk and Dr. Deepti Radia talk about Acute Myeloid Leukaemia in the context of the EU approval of RYDAPT in newly diagnosed FLT3+ AML.
AML is the most common acute leukaemia in adults. In this video, Dr. Schlenk discusses various genetic changes observed in AML with emphasis on the FLT3 gene.
In this video, Dr. Schlenk and Dr. Radia discuss FLT3 mutation testing and the importance of FLT3-ITD and FLT3-TKD mutations.
In this video, Dr. Schlenk and Dr. Radia discuss a hypothetical case of a patient who has newly diagnosed AML.
In this video, Dr. Schlenk discusses the RATIFY clinical trial of RYDAPT in adults with newly diagnosed FLT3+ AML.
In this short video, Dr. Schlenk summarises the RYDAPT indication in newly diagnosed FLT3+ AML based on the pivotal RATIFY study.
In this video, Dr. Schlenk answers questions regarding his experience in using RYDAPT to treat patients with AML.
FLT3, FMS-like tyrosine kinase 3; ITD, internal tandem duplication; TKD, tyrosine kinase domain.